Conditional sentence

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024

In 2023, Airdoc Technology significantly accelerated its commercialization,while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization,while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

AI Stocks Targeting Opportunities in the Global Healthcare Market

Retrieved on: 
Wednesday, April 10, 2024

The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.

Key Points: 
  • The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.
  • Betting on healthcare as a key market, Avant Technologies, Inc. (OTCQB: AVAI) just announced the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health.
  • "By helping healthcare companies easily build and manage AI solutions, we're enabling them to harness the full power and potential of generative AI."
  • For investors following AI stocks, the hunt is on for finding the stocks that can harness the power of AI for the next generation of healthcare.

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
Monday, March 18, 2024

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

Avant Technologies Acquires Wired-4-Health, Advancing AI Interoperability in Healthcare Data

Retrieved on: 
Tuesday, April 9, 2024

LAS VEGAS, April 09, 2024 (GLOBE NEWSWIRE) -- Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI and AI infrastructure solutions, today announces the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health.

Key Points: 
  • LAS VEGAS, April 09, 2024 (GLOBE NEWSWIRE) -- Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI and AI infrastructure solutions, today announces the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health.
  • Unified by a shared objective to propel the healthcare data interoperability landscape forward, this strategic merger leverages cutting-edge AI and amplified computational capabilities.
  • This potent combination empowers healthcare and life sciences organizations to navigate the complexities of system interoperability with unprecedented efficiency, enhanced performance, improved data integrity, and a more cost-effective, scalable infrastructure.
  • “Completion of this important strategic acquisition enables us to deliver best-in-class data and system interoperability services to the healthcare and life sciences sectors powered by AvantAI® and our high-density compute capabilities,” said Tim Lantz, Chief Executive Officer of Avant Technologies.

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Retrieved on: 
Tuesday, April 9, 2024

Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Key Points: 
  • Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
  • “Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP—something most patients find undesirable.
  • Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases,” said Kirk Huntsman, Vivos Chairman and Chief Executive Officer.
  • “We are very pleased the Centers for Medicare and Medicaid Services (CMS) recognizes and validates the benefits our FDA cleared devices can have on the lives of patients diagnosed with OSA.

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Retrieved on: 
Monday, April 8, 2024

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.
  • He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022.
  • He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.
  • Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners.

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
Saturday, April 6, 2024

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, April 4, 2024

At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Key Points: 
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.
  • Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial.
  • Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
Thursday, April 4, 2024

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

AAFA's Advocacy for Health Equity Leads to White House Address on Asthma Inhaler Pricing

Retrieved on: 
Wednesday, April 3, 2024

The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.

Key Points: 
  • The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.
  • “On behalf of the 27 million people in the United States with asthma, we appreciate the leadership of President Biden and Senator Sanders to bring down costs for asthma treatments.
  • Pricing announcements made in March by some manufacturers of inhalers will mean lower costs and improved access to asthma medicine for many people with asthma starting this June,” stated Mendez.
  • “Lower out-of-pocket costs have the potential to drastically improve asthma health outcomes.